All In Biotech

Drug Trial Radar · NCT05818683

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 26, 2023

Primary completion

Aug 31, 2027

Study completion May 23, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Conditions

  • Metastatic Castration-resistant Prostate Neoplasms
  • Metastatic Hormone-sensitive Prostate Cancer

Interventions

  • PasritamigDrug

    Pasritamig will be administered.

  • CetrelimabDrug

    Cetrelimab will be administered by intravenous infusion.

  • CabazitaxelDrug

    Cabazitaxel will be administered by intravenous infusion.

  • DocetaxelDrug

    Docetaxel will be administered by intravenous infusion.

  • ApalutamideDrug

    Apalutamide will be administered orally.

  • EnzalutamideDrug

    Enzalutamide will be administered orally.

  • DarolutamideDrug

    Darolutamide will be administered orally.

  • Abiraterone acetate plus prednisone (AAP)Drug

    Abiraterone acetate plus prednisone (AAP) will be administered orally.

  • Lutetium Lu-177 vipivotide tetraxetanDrug

    Lutetium Lu-177 vipivotide tetraxetan will be administered intravenously.

  • JNJ-101556143Drug

    JNJ-101556143 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 21 days after first dose of combination agent
  2. Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 2 years 11 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Start Midwest

    Grand Rapids, Michigan · Recruiting

  • Perlmutter Cancer Center at NYU Langone Brooklyn

    Brooklyn, Mississippi · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Sidney Kimmel Cancer Center - Jefferson Health

    Philadelphia, Pennsylvania · Recruiting

  • Icon Cancer Centre Kurralta Park

    Adelaide, Australia · Recruiting

  • Macquarie University

    Macquarie Park, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Hosp Univ Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain · Recruiting

  • Hosp Univ Hm Sanchinarro

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.